NADMED has secured €3.5 million in Series A funding to expand its innovative NAD testing technology internationally, emphasizing its application in personalized medicine.

Target Overview

NADMED is a Finnish biotech company headquartered in Helsinki, which has recently secured €3.5 million in Series A funding aimed at expanding its pioneering NAD testing technology on an international scale, particularly targeting the U.S. market. This state-of-the-art technology introduces the first method to measure all four forms of NAD (vitamin B3) and glutathione directly from fresh blood within hours. These crucial biomolecules play significant roles in energy production and cellular repair, with their imbalances linked to various age-related diseases such as metabolic disorders, cancer, and neurodegenerative conditions.

The investment process was led by Nordic Science Investments (NSI) and saw participation from Voima Ventures and University of Helsinki Funds. This funding milestone is deemed significant for the progress of personalized medicine. Jari Närhi, CEO and co-founder of NADMED, remarked, "In the coming years, metabolism will be the hottest topic in medicine and biology, especially when applied to personalized health and disease understanding." He further emphasized that this substantial investment will enhance capabilities in diagnostics, therapy monitoring, and the overall advancement of metabolic science for the collective benefit of society.

Industry Overview in Finland

The Finnish biotech sector has seen considerable growth over the past decade, becoming a significant contributor to the global biotechnology industry. Government initiatives and strong public-private partnerships in Finland have fostere